Renal Cancer - Results from #5060

Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma September 14, 2017

Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy September 13, 2017

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing September 13, 2017

Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies September 12, 2017

Surgical management of metastatic renal cell carcinoma September 12, 2017

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial September 11, 2017

Second-line systemic therapy in metastatic renal-cell carcinoma: A review September 11, 2017

Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study September 11, 2017

Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma September 8, 2017

Nephron-sparing Suture of Renal Parenchyma After Partial Nephrectomy: Which Technique to Go For? Some Best Practices September 8, 2017

[Ablative therapy in kidney cancer: Indications] September 8, 2017

[A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial] September 7, 2017

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer September 7, 2017

Application of the American Society of Clinical Oncology frameworks to compare tyrosine kinase inhibitors used in first line treatment of metastatic renal cell carcinoma: Had we solved the mystery? September 6, 2017

Integration of RNA-Seq and RPPA data for survival time prediction in cancer patients September 6, 2017

Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers September 5, 2017

Imaging strategy and outcome following partial nephrectomy September 5, 2017

Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation September 3, 2017

PBRM1 regulates proliferation and the cell cycle in renal cell carcinoma through a chemokine/chemokine receptor interaction pathway September 1, 2017

Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation September 1, 2017

Page 254 of 460